Skip to main content
Log in

Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease

  • Neurology and Preclinical Neurological Studies - Short communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa treated patients with Parkinson’s disease after first time intake of an irreversible monoamine oxidase-B inhibitor. One patient received 10 mg selegiline and eleven patients took 1 mg rasagiline. A significant decrease of monoamine oxidase-B activity appeared 2 and 4 h following monoamine oxidase-B inhibitor intake in comparison to baseline. We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  • Bar AO, Amit T, Youdim MB (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169–172

    Article  Google Scholar 

  • Bartl J, Müller T, Grünblatt E, Gerlach M, Riederer P (2014) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 121:379–383

    Article  CAS  PubMed  Google Scholar 

  • Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykko KA, Lammintausta RA (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 37:602–609

    Article  CAS  PubMed  Google Scholar 

  • Müller T (2010) The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Clin Med Insights Therap 2:155–168

    Article  Google Scholar 

  • Müller T, Foley P (2017) Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet 56:251–261

    Article  PubMed  Google Scholar 

  • Müller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm 120:761–765

    Article  PubMed  Google Scholar 

  • Nag S, Lehmann L, Kettschau G, Toth M, Heinrich T, Thiele A, Varrone A, Halldin C (2013) Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). Bioorg Med Chem 21:6634–6641

    Article  CAS  PubMed  Google Scholar 

  • Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 25:193–204

    Article  CAS  PubMed  Google Scholar 

  • Riederer P, Laux G (2011) MAO-inhibitors in Parkinson’s Disease. Exp Neurobiol 20:1–17

    Article  PubMed  PubMed Central  Google Scholar 

  • Riederer P, Müller T (2017) Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol 13:233–240

    Article  CAS  PubMed  Google Scholar 

  • Treseder SA, Rose S, Summo L, Jenner P (2003) Commonly used l-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm (Vienna) 110:229–238

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the patients and Gabi Öhm, Kathrin Eilert, Marion Marg, Hartmut Rothe, Matthias Küchler, Sven Lütge, Thomas Haas.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Müller.

Ethics declarations

Funding

This investigation was supported by an unrestricted grant from the "Verein zur Durchführung Neurowissenschaftliche Tagungen e.V.", Würzburg, Germany.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müller, T., Riederer, P. & Grünblatt, E. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease. J Neural Transm 124, 745–748 (2017). https://doi.org/10.1007/s00702-017-1705-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-017-1705-z

Keywords

Navigation